Korro Bio Reports Zero Revenue and $0.98 Loss in Third Quarter
Korro Bio reported no collaboration revenue in the third quarter, down from $1.1 million a year earlier, while its net loss narrowed. Lower research and development costs, primarily following termination of the KRRO-110 trial and workforce reductions, more than offset higher costs for the KRRO-121 and KRRO-111 programs.
Korro Bio reported no collaboration revenue in the third quarter, compared with $1.1M a year earlier, while its net loss narrowed. Lower research and development costs, primarily after termination of the KRRO-110 trial and workforce reductions, more than offset higher KRRO-121 and KRRO-111 program…